Orca Bio

For patients with acute myeloid leukemia (AML), high-precision therapy matters because treatment carries serious risks.     In recognition of #AMLWorldAwarenessDay this week, we want to highlight the burden of serious treatment-related risks, including infection and graft versus host disease (GVHD), on patients and caregivers affected by AML.     That is why we are developing investigational high-precision cell therapies for high-risk blood cancers, including AML. Learn more about our approach: https://lnkd.in/dAGuh6gS #KnowAML 

Join our Senior Medical Director, Anna Pavlova, next week at the Clinical Trials in Oncology West Coast Conference for insights into navigating trial complexity, overcoming key barriers and advancing innovation in oncology. Learn more: https://lnkd.in/gPkRAp8C #ClinicalTrials #CellTherapy #GeneTherapy

#TeamOrcaBio will be in San Diego next week to participate in #FiercePharmaEngage. Andrea Blank, Vice President of Medical Affairs, and Adria Carbo, Ph.D., Head of Business Development, will join this year’s program. Looking forward to joining the conversation on key issues shaping biopharma! https://lnkd.in/eRhP2ACM

For #WorldHealthDay, we’re reflecting on the importance of coming together to move healthcare forward.     Progress in cell therapy is built on collaboration across research, care delivery and patient support. At Orca Bio, we’re proud to be part of that shared effort and to help translate innovation into meaningful impact for patients and families. We #StandWithScience in service of better possibilities for patients.     Learn more about our approach: https://lnkd.in/d6A3aPfx 

Today, we announced that the FDA has extended the review timeline for our Biologics License Application for our investigational treatment for hematologic malignancies.    Read the full press release:  https://bit.ly/3PJ79aD 

#ICYMI: Last week, our team was on the ground in Madrid for the 52nd Annual Meeting of the EBMT. It was an energizing week of scientific exchange and meaningful conversations with colleagues from across the global transplant community. We’re grateful for the opportunity to share our work and connect with so many dedicated to advancing care for patients worldwide. #EBMT26 #CellTherapy #Hematology

On #ScienceAppreciationDay, we celebrate the power of science to transform lives. Today is a reminder that every breakthrough begins with rigorous research, bold ideas and the people dedicated to advancing them.       Interested in learning more about our work? https://lnkd.in/dAGuh6gS      #ScienceSaves #CellTherapy  

We are proud to be named one of Fast Company’s "Most Innovative Companies" of 2026! This recognition reflects our team’s focus on pioneering high-precision cell therapies, with the goal of improving outcomes for patients who need them most. We’re grateful to Fast Company for the honor, and even more grateful to our team at Orca Bio who makes this work possible every day. Learn more about why Fast Company named us one of the most innovative companies in Biotech: https://bit.ly/4lQcwAD #FCMostInnovative #TeamOrcaBio

This month, our Senior Medical Director, Anna Pavlova, and her partner, Bryan Schwab, were in Japan to participate in the Tokyo Marathon 2026 with Team Blood Cancer United. Thank you for helping raise critical funds to support patients with blood cancer and their families. We’re proud to see our community advancing this mission both within and beyond our company walls. #PatientsFirst #BloodCancer #Hematology #CellTherapy

Though many patients receiving a conventional allogeneic or autologous transplant experience treatment success, certain cells may contribute to complications such as chronic GVHD.    At Orca Bio, we’re advancing high‑precision allogeneic cell therapy strategies designed to improve post‑transplant outcomes while supporting long‑term disease control.    Learn more about our pipeline of investigational precision‑engineered allogeneic cell therapies: https://lnkd.in/gRbbgRe4   #CellTherapy #Hematology #PrecisionMedicine